Bausch Health's 2026Q2 results show a dramatic gross margin spike to 99.0% and operating margin of 40.2%, but this appears unsustainable given prior quarters' margins around 60% and revenue declining 28.5% year-over-year. The company's balance sheet remains st...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $1.26+31.3% vs $0.96 | $2.8B+8.7% vs $2.6B |
Q2 2026 Apr 29, 2026 | $0.78-3.7% vs $0.81 | $2.5B+4.3% vs $2.4B |
Q1 2026 Feb 18, 2026 | $1.08-10.7% vs $1.21 | $2.8B+2.1% vs $2.7B |
Q4 2025 Oct 29, 2025 | $1.16+8.4% vs $1.07 | $2.7B-1.0% vs $2.7B |
Engineers Gate Manager LP grew its holdings in Bausch Health Cos Inc. (NYSE: BHC) by 149.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 249,991 shares of the company's stock after purchasing an additional 149,820 shares during the quarter. Engineers
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan. LAVAL, QC, Sept.
This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program.
Benchmark BHC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bausch Health Companies Inc. (BHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.71 | $2.13B | 13.28 | 8.53% | 1.53% | 588.24% | — | |
| $45.92 | $2.18B | 11.74 | -4.31% | 15.57% | 9.22% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $17.05 | $6.09B | -16.72 | 6.47% | -3.14% | -2.58% | — | |
| $56.07 | $10.94B | 29.98 | 5.06% | 13.46% | 6.88% | — | |
| $103.53 | $180.32B | 27.83 | 5.67% | 13.91% | 12.09% | — |
Bausch Health Companies Inc. (BHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bausch Health Companies Inc. (BHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 1, 2026·SEC
May 19, 2026·SEC
Get notified when BHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bausch Health Companies Inc. (BHC) stock FAQ — growth, dividends, profitability & financials explained
Bausch Health Companies Inc. (BHC) reported $9.82B in revenue for fiscal year 2025. This represents a 14686% increase from $66.4M in 1996.
Bausch Health Companies Inc. (BHC) grew revenue by 8.5% over the past year. This is steady growth.
Bausch Health Companies Inc. (BHC) reported a net loss of $1.08B for fiscal year 2025.
Bausch Health Companies Inc. (BHC) has a return on equity (ROE) of 588.2%. This is excellent, indicating efficient use of shareholder capital.
Bausch Health Companies Inc. (BHC) generated $1.47B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
